These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

928 related items for PubMed ID: 1900308

  • 1. Soluble fibrin degradation products potentiate tissue plasminogen activator-induced fibrinogen proteolysis.
    Weitz JI, Leslie B, Ginsberg J.
    J Clin Invest; 1991 Mar; 87(3):1082-90. PubMed ID: 1900308
    [Abstract] [Full Text] [Related]

  • 2. Standard and low molecular weight heparin have no effect on tissue plasminogen activator induced plasma clot lysis or fibrinogenolysis.
    Weitz JI, Kuint J, Leslie B, Hirsh J.
    Thromb Haemost; 1991 May 06; 65(5):541-4. PubMed ID: 1651568
    [Abstract] [Full Text] [Related]

  • 3. Effects of low molecular weight heparins on fibrin polymerization and clot sensitivity to t-PA-induced lysis.
    Parise P, Morini M, Agnelli G, Ascani A, Nenci GG.
    Blood Coagul Fibrinolysis; 1993 Oct 06; 4(5):721-7. PubMed ID: 8292721
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Like fibrin, (DD)E, the major degradation product of crosslinked fibrin, protects plasmin from inhibition by alpha2-antiplasmin.
    Lee AY, Fredenburgh JC, Stewart RJ, Rischke JA, Weitz JI.
    Thromb Haemost; 2001 Mar 06; 85(3):502-8. PubMed ID: 11307822
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Vampire bat salivary plasminogen activator promotes robust lysis of plasma clots in a plasma milieu without causing fluid phase plasminogen activation.
    Hare TR, Gardell SJ.
    Thromb Haemost; 1992 Aug 03; 68(2):165-9. PubMed ID: 1412162
    [Abstract] [Full Text] [Related]

  • 8. Potentiation by Lys-plasminogen of clot lysis by single or two chain urokinase-type plasminogen activator or tissue-type plasminogen activator.
    Watahiki Y, Scully MF, Ellis V, Kakkar VV.
    Thromb Haemost; 1989 Jun 30; 61(3):502-6. PubMed ID: 2508259
    [Abstract] [Full Text] [Related]

  • 9. Absence of synergism between tissue-type plasminogen activator (t-PA), single-chain urokinase-type plasminogen activator (scu-PA) and urokinase on clot lysis in a plasma milieu in vitro.
    Collen D, De Cock F, Demarsin E, Lijnen HR, Stump DC.
    Thromb Haemost; 1986 Aug 20; 56(1):35-9. PubMed ID: 3095946
    [Abstract] [Full Text] [Related]

  • 10. A precise and rapid microtitre plate clot lysis assay: methodology, kinetic modeling and measurement of catalytic constants for plasminogen activation during fibrinolysis.
    Jones AJ, Meunier AM.
    Thromb Haemost; 1990 Nov 30; 64(3):455-63. PubMed ID: 2128976
    [Abstract] [Full Text] [Related]

  • 11. Fibrin-specific thrombolytic agents.
    Collen D.
    Klin Wochenschr; 1988 Nov 30; 66 Suppl 12():15-23. PubMed ID: 3126344
    [Abstract] [Full Text] [Related]

  • 12. Characterization of the interactions of plasminogen and tissue and vampire bat plasminogen activators with fibrinogen, fibrin, and the complex of D-dimer noncovalently linked to fragment E.
    Stewart RJ, Fredenburgh JC, Weitz JI.
    J Biol Chem; 1998 Jul 17; 273(29):18292-9. PubMed ID: 9660794
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Molecular mechanisms of fibrinolysis and their application to fibrin-specific thrombolytic therapy.
    Collen D.
    J Cell Biochem; 1987 Feb 17; 33(2):77-86. PubMed ID: 3553213
    [Abstract] [Full Text] [Related]

  • 16. In vitro clot lysis as a potential indicator of thrombus resistance to fibrinolysis--study in healthy subjects and correlation with blood fibrinolytic parameters.
    Colucci M, Scopece S, Gelato AV, Dimonte D, Semeraro N.
    Thromb Haemost; 1997 Apr 17; 77(4):725-9. PubMed ID: 9134650
    [Abstract] [Full Text] [Related]

  • 17. Biochemical and biological properties of a recombinant tissue-type plasminogen activator derived from the rat JMI-229 cell line.
    Lijnen HR, Webb PD, Van Hoef B, De Cock F, Stassen JM, Prior SD, Collen D.
    Thromb Haemost; 1992 Feb 03; 67(2):239-47. PubMed ID: 1621244
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. The relative kinetics of clotting and lysis provide a biochemical rationale for the correlation between elevated fibrinogen and cardiovascular disease.
    Kim PY, Stewart RJ, Lipson SM, Nesheim ME.
    J Thromb Haemost; 2007 Jun 03; 5(6):1250-6. PubMed ID: 17266698
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 47.